Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2023 | Clinical relevance of constitutive VLA-4 activation in CLL patients treated with ibrutinib

Erika Tissino • 8 Oct 2023
iwCLL 2023
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors Ibrutinib

In this interview, Erika Tissino, PhD, CRO National Cancer Institute, Aviano, Italy, discusses an abstract on constitutive VLA-4 activation and how this activation links to BCR autonomous signaling in circulating chronic lymphocytic leukemia (CLL) cells, leading to promotion of pro-survival signals. Dr Tissino explains how this mechanism may affect clinical outcomes of CLL patients treated with ibrutinib.This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals